A Randomized, single-center, open-label, single dose, two-period, crossover study to investigate the relative bioavailability of Binimetinib 3 x15 mg and 45 mg tablets in healthy participants
A Randomized, single-center, open-label, single dose, two-period, crossover study to investigate the relative bioavailability of Binimetinib 3 x15 mg and 45 mg tablets in healthy participants
Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations
A Randomized, single-center, open-label, single dose, two-period, crossover study to investigate the relative bioavailability of Binimetinib 3 x15 mg and 45 mg tablets in healthy participants
Status
Status :
Active not recruiting
Type of study
Phase I
Min. Age
18
Years old
Max. Age
65
Years old
Gender
All
Therapeutic area :
Oncology
Disease :
Melanoma
Study medication :
Binimetinib (MEKTOVI®)
Phase :
Phase I
Start Date :
03 September 2021
End date :
19 November 2021
Study ID :
W00074 CI 101
EudraCT/CTIS number :
2022-000610-34
CT.gov Number :
NCT05103891
Send by email